Epinomics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Acquired | Acquired

About Epinomics

Epinomics is developing technologies for epigenetics research.

Epinomics Headquarter Location

Menlo Park, California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Epinomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Epinomics is included in 1 Expert Collection, including Omics.



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Latest Epinomics News

10x Genomics Acquires Epinomics

Dec 26, 2018

Furthers 10x Leadership across Genomics Applications Brings Inventors of ATAC-seq Technology to 10x PLEASANTON, Calif., Aug. 28, 2018 /PRNewswire/ —  10x Genomics , a leader in the genomics field, today announced its first acquisition with  Epinomics , a pioneer in the growing epigenetics space. The acquisition will give 10x Genomics ATAC-seq technology and fundamental IP to accelerate discoveries and further research in epigenomics, paving the way for a new understanding of disease, diagnostics and therapeutics. 10x Genomics will immediately integrate Epinomics’ proprietary epigenetic technology into its  Chromium Single Cell ATAC Solution , which is expected to launch by the end of this year, offering researchers and pharmaceutical companies tools to better understand biological mechanisms. 10x Genomics builds tools and applications that leverage advances in sequencing along with innovations in hardware, chemistry and software. The genomics market is seeing exponential growth and is estimated to be at approximately  $24 billion by 2022 . Today, 10x Genomics is the leader in single-cell and other emerging areas of genomic analysis enabling greater resolution to accelerate the understanding of new biology and disease. Its customers have already analyzed over 130 million single cells, broadly equivalent to sequencing 18,000 human genomes. “Our goal is to accelerate science and enable our customers to see biology they could not see before,” said Serge Saxonov, CEO and co-founder of 10x Genomics. “Today’s acquisition gives us a strong team, IP and technology that has been enthusiastically validated by customers. It provides a foundation for powerful new products and positions us well to become the leader in epigenomics.” Epinomics was founded by the team that developed the ATAC-seq technology, a ground-breaking approach to measure and understand the epigenome. Its technology and analytics platform has been adopted by scientific institutions and commercial organizations. Epinomics’ patent portfolio, which includes foundational issued IP relating to ATAC-seq, enhances and complements 10x Genomics’ existing patent portfolio which covers high throughput single cell applications for ATAC-seq and other epigenetic applications. Epinomics is backed by leading venture capital firms including  Lightspeed Venture Partners ,  Felicis Ventures , and  Founders Fund . “With Epinomics joining 10x Genomics, single cell epigenetics will now be available to a broader base of investigators across academic and commercial organizations,” said Howard Chang, professor of Dermatology and Genetics at Stanford University School of Medicine, co-inventor of ATAC-seq and a scientific co-founder of Epinomics. “The innovations coming out of this acquisition will propel the genomics field forward.” “We are excited to be joining forces with 10x Genomics to transform research and advance healthcare by leveraging cutting-edge scientific technology and deep data analytics,” added Fergus Chan, co-founder and CEO of Epinomics. Chan and his co-founder, Paul Giresi, a co-inventor of the ATAC-seq technology, and the Epinomics team will join 10x Genomics immediately. The scientific co-founders, Chang and Will Greenleaf, assistant professor in Genetics at Stanford University School of Medicine and co-inventor of ATAC-seq, will join as scientific advisors to 10x Genomics. Both have done pioneering work in genetics including inventing new methods for epigenomic profiling, discovering new classes of genes, and have been published extensively. About 10x Genomics 10x Genomics is a leading company in the field of genomics. The company was founded on the vision that this century will bring unprecedented advances in biomedicine to transform the way we understand and treat diseases leading to dramatic improvements in human health. 10x products enable the acceleration of genetic discoveries through unparalleled resolution leading to a new understanding of biology and diseases. The company’s customers include leading biomedical research institutes, pharmaceutical companies and clinical centers. Founded in 2012, 10x Genomics is financed by marquee global investors including Paladin Capital Group ,  Venrock ,  Softbank ,  Foresite Capital ,  Fidelity , and  Meritech Capital . For more information, visit  www.10xgenomics.com . Media Enquiries

  • When was Epinomics founded?

    Epinomics was founded in 2013.

  • Where is Epinomics's headquarters?

    Epinomics's headquarters is located at Menlo Park.

  • What is Epinomics's latest funding round?

    Epinomics's latest funding round is Acquired.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.